Goldman Sachs Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK) Gets a Hold From Barclays
Analyst Issues Sell Rating for GlaxoSmithKline Amid Market Share and Litigation Concerns
Berenberg Bank Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Maintains Target Price $46
Deutsche Bank Keeps Their Buy Rating on GlaxoSmithKline (GSK)
Maintaining Sell Rating on GlaxoSmithKline: Analyzing COPD Market Challenges and Growth Concerns
Deutsche Bank Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
Analyst Issues Sell Rating for GlaxoSmithKline Amid Legal Challenges and Financial Risks
Barclays Remains a Hold on GlaxoSmithKline (GSK)
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Berenberg Bank Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Maintains Target Price $46
Argus Research Remains a Buy on GlaxoSmithKline (GSK)
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Citi Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
Kepler Capital Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
BofA Securities Maintains GlaxoSmithKline(GSK.US) With Sell Rating
Bank of America Securities Sticks to Their Sell Rating for GlaxoSmithKline (GSK)
Deutsche Bank Keeps Their Buy Rating on GlaxoSmithKline (GSK)
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
GlaxoSmithKline Sell Rating Justified by Arexvy Underperformance and Reduced Revenue Projections